Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA)
CUSIP: 640979100
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 180,804,723
- Total 13F shares
- 12,834,662
- Share change
- -497,130
- Total reported value
- $25,025,340
- Price per share
- $1.95
- Number of holders
- 41
- Value change
- -$965,819
- Number of buys
- 13
- Number of sells
- 13
Quarterly Holders Quick Answers
What is CUSIP 640979100?
CUSIP 640979100 identifies NMRA - Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 640979100:
Top shareholders of NMRA - Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| AMGEN INC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
35,368,653
|
$423,716,463 | — | 19 Sep 2023 | |
| ARCH Venture Fund XII, L.P. |
13D/G
|
Kristina Burow |
19%
|
33,965,419
|
$69,289,455 | +$13,162 | 30 Mar 2026 | |
| FMR LLC |
3/4/5
13D/G
13F
|
Other* · Company |
2.2%
from 13D/G
|
5,624,353
|
$67,379,749 | — | 19 Sep 2023 | |
| Kristina Burow |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
33,975,555
mixed-class rows
|
$66,466,963 | +$4,999,977 | 27 Oct 2025 | |
| ARCH Venture Partners X, LLC |
3/4/5
|
10%+ Owner |
19%
|
33,847,838
|
$66,380,119 | +$4,999,977 | 27 Oct 2025 | |
| ARCH Venture Partners XII, LLC |
3/4/5
|
10%+ Owner |
19%
|
33,847,838
|
$66,380,119 | +$4,999,977 | 27 Oct 2025 | |
| Paul L. Berns |
3/4/5
13D/G
|
Title: Chief Executive Officer and Chairman of the Board, Director |
5.1%
from 13D/G
|
9,178,282
mixed-class rows
|
$26,224,179 | -$34,459 | 17 Feb 2026 | |
| K2 HealthVentures Equity Trust LLC |
13D/G
|
— |
5%
|
8,997,035
|
$19,253,655 | -$5,136,588 | 31 Dec 2025 | |
| Invus Global Management, LLC |
13D/G
|
Raymond Debbane |
4.7%
|
8,497,822
|
$16,570,753 | -$975,000 | 31 Mar 2026 | |
| SOFTBANK GROUP CORP. |
13F
|
Company |
3.6%
|
6,429,720
|
$11,509,199 | — | 31 Dec 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
3.5%
|
6,288,783
|
$11,256,922 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.5%
|
4,539,261
|
$8,125,277 | — | 31 Dec 2025 | |
| MIC Capital Management UK LLP |
13F
|
Company |
2.5%
|
4,460,700
|
$7,984,654 | — | 31 Dec 2025 | |
| Gosebruch Henry O |
3/4/5
|
President & CEO, Director |
—
mixed-class rows
|
749,793
mixed-class rows
|
$7,065,720 | — | 14 Feb 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2%
|
3,673,839
|
$6,576,172 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2%
|
3,616,514
|
$6,473,560 | — | 31 Dec 2025 | |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST |
13F
|
Company |
1.8%
|
3,309,123
|
$5,923,330 | — | 31 Dec 2025 | |
| ICONIQ Capital, LLC |
13F
|
Company |
1.4%
|
2,559,090
|
$4,580,771 | — | 31 Dec 2025 | |
| Carol Y. Suh |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
544,674
mixed-class rows
|
$4,488,595 | — | 14 Feb 2024 | |
| Lunate Capital Ltd |
13F
|
Company |
1.2%
|
2,124,143
|
$3,802,216 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
1.1%
|
2,024,944
|
$3,624,649 | — | 31 Dec 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
1%
|
1,849,445
|
$3,310,507 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.8%
|
1,445,902
|
$2,588,165 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.72%
|
1,307,688
|
$2,340,762 | — | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.71%
|
1,278,408
|
$2,288,351 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.62%
|
1,128,972
|
$2,020,860 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.6%
|
1,083,400
|
$1,939,286 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.56%
|
1,003,746
|
$1,797,457 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.53%
|
967,235
|
$1,731,351 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.47%
|
858,502
|
$1,536,719 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.41%
|
738,272
|
$1,321,507 | — | 31 Dec 2025 | |
| AlphaCore Capital LLC |
13F
|
Company |
0.35%
|
638,784
|
$1,143,423 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.32%
|
583,758
|
$1,044,927 | — | 31 Dec 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.3%
|
534,044
|
$956,000 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.28%
|
512,470
|
$917,321 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.28%
|
505,803
|
$905,387 | — | 31 Dec 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.26%
|
474,480
|
$849,319 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.22%
|
388,919
|
$696,165 | — | 31 Dec 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.19%
|
335,267
|
$600,128 | — | 31 Dec 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.17%
|
314,119
|
$562,273 | — | 31 Dec 2025 | |
| Robert A. Lenz |
3/4/5
|
Head of R&D |
—
mixed-class rows
|
409,092
mixed-class rows
|
$516,616 | — | 18 Feb 2025 | |
| Joshua Pinto |
3/4/5
|
President |
—
mixed-class rows
|
1,409,950
mixed-class rows
|
$514,682 | -$21,093 | 17 Feb 2026 | |
| Cerity Partners LLC |
13F
|
Company |
0.15%
|
275,112
|
$492,450 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.13%
|
238,484
|
$426,886 | — | 31 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.13%
|
239,309
|
$426,000 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.13%
|
227,594
|
$407,393 | — | 31 Dec 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
225,000
|
$402,750 | — | 31 Dec 2025 | |
| Graham Capital Management, L.P. |
13F
|
Company |
0.11%
|
191,416
|
$342,635 | — | 31 Dec 2025 | |
| Matthew K. Fust |
3/4/5
|
Director |
—
mixed-class rows
|
100,100
mixed-class rows
|
$342,395 | — | 28 May 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.1%
|
185,832
|
$332,639 | — | 31 Dec 2025 |
Institutional Holders of Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) as of Q1 2026
As of 31 Mar 2026,
Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,834,662 shares.
The largest 10 holders included
VANGUARD CAPITAL MANAGEMENT LLC, WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST, Lunate Capital Ltd, JANE STREET GROUP, LLC, VANGUARD FIDUCIARY TRUST CO, DIMENSIONAL FUND ADVISORS LP, FEDERATED HERMES, INC., GSA CAPITAL PARTNERS LLP, Invesco Ltd., and VANGUARD PORTFOLIO MANAGEMENT LLC.
This page lists
41
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
100
Q1 2026 holders
41
Holder diff
-59
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.